We are live on
!
Find out more
KXA
KPCB XIII Associates Portfolio holdings
AUM
$186M
1-Year Est. Return
11.23%
This Fund
S&P 500
This Quarter
Est. Return
-17.28%
1 Year Est. Return
-11.23%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$210M
AUM Growth
–
Cap. Flow
+$243M
Cap. Flow
% of AUM
115.93%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
2
New
2
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Progyny
PGNY
|
+$234M |
| 2 |
Pulmonx
LUNG
|
+$9.46M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Progyny
PGNY
$2.4B
| $202M | 96.01% |
+6,473,515
| New | +$234M |
|
|
2
Pulmonx
LUNG
$51.5M
| $8.39M | 3.99% |
+994,971
| New | +$9.46M |
|
Similar funds
BC
CC
BAG
SWA
DLG
NFAM
RCGI
TA
KPCB XIII Associates's Q4 2022 Portfolio in Review
Q4 2022 is the first quarter with a 13F filing on record for KPCB XIII Associates, which disclosed 2 positions worth $210M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Progyny: 6,473,515 shares worth $202M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- KPCB XIII Associates's largest Q4 2022 buy was Progyny: 6,473,515 shares worth $202M.
- KPCB XIII Associates's ten largest holdings make up 100% of its $210M portfolio in Q4 2022.
- KPCB XIII Associates disclosed 2 positions in Q4 2022, its first 13F filing on record.
Based on KPCB XIII Associates's 13F filing for Q4 2022, filed 7 Feb 2023.